Skip to main content
. 2024 Jul 25;12(8):840. doi: 10.3390/vaccines12080840

Figure 2.

Figure 2

The humoral response against SARS-CoV-2 variants Omicron XBB.1.16, Omicron XBB.1.5, and Omicron JN.1 induced by BNT62n2 XBB and PHH-1V81 at day 14. (A) The GMT for the adjusted treatment against the Omicron XBB.1.16 variant for each vaccinated group (PHH-1V81 group; n = 406 and BNT62b2 XBB; n = 193) by PBNA; (B) the GMT for the adjusted treatment against the Omicron XBB.1.5 variant for each vaccinated group (PHH-1V81 group; n = 406 and BNT62b2 XBB; n = 193) by PBNA; (C) the GMT for the adjusted treatment against the Omicron JN.1 variant for a subset of n = 100 participants (n = 65 with PHH-1V81 and n = 35 with BNT62b2 XBB1.5) by VNA. Graphics (A–C) represent the mean GMT with 95% CI at baseline (with a bar) and 14 days after booster (dark grey bar); the upper numbers represent the mean GMFR at day 14 from the baseline. CI: confidence interval; GMT: geometric mean titer; GMFR: geometric mean fold rise.